Cathepsin

Cathepsin C-IN-3 is a selective inhibitor of Cathepsin C, demonstrating a potency with an IC50 value of 61.79 nM. This compound effectively inhibits the proliferation of THP-1 and U937 cell lines, with IC50 values of 101.5 nM and 86.5 nM, respectively. Cathepsin C-IN-3 is valuable for studies focused on the role of Cathepsin C in inflammation and immune responses.

Cathepsin C-IN-7 is a selective inhibitor of Cathepsin C, an enzyme implicated in various inflammatory and cancer-related processes. This compound demonstrates significant biological activity in modulating immune responses and has potential applications in the study of primary cancers and cancer metastases. Researchers can utilize Cathepsin C-IN-7 to investigate the role of Cathepsin C in tumor biology and the progression of malignancies.

MV061194 is a selective inhibitor of cathepsin K, exhibiting a human Ki of 2.5 nM. This compound is utilized in research focused on osteoporosis, providing insights into bone resorption processes and potential therapeutic strategies for bone-related disorders. Its specificity and potency make it a valuable tool for studying the role of cathepsin K in various biological contexts.

Cathepsin K inhibitor 5 is a selective inhibitor of Cathepsin K, a cysteine protease involved in bone resorption and remodeling. This compound effectively inhibits Cathepsin K activity, making it valuable for studying osteoclast function and bone-related diseases such as osteoporosis. Its use in research can enhance understanding of bone metabolism and aid in the development of novel therapeutic strategies for bone disorders.

TB-9 is a potent inhibitor of cathepsin D, cathepsin E, and BACE1, exhibiting IC50 values of 0.0783 nM, 0.724 nM, and 54.2 nM, respectively. This compound shows significant potential in the study of neurodegenerative diseases and cancer, where cathepsin activity is implicated. Its ability to selectively target these enzymes makes TB-9 an important tool for researchers investigating the role of proteases in various biological processes.

Cathepsin K-IN-8 is a potent inhibitor of cathepsin K, an enzyme involved in the degradation of extracellular matrix components. This compound is primarily utilized in research focused on inflammatory diseases such as rheumatoid arthritis and osteoarthritis, as well as conditions like osteoporosis and tumor progression. Its inhibition of cathepsin K allows for the investigation of its role in these pathological processes, making it a valuable tool for studying bone resorption and related disorders.

BI-1124 is a selective inhibitor of cathepsin S, a cysteine protease involved in various pathological processes, including inflammation and tissue remodeling. This compound demonstrates effective ocular pharmacokinetic-pharmacodynamic properties in rabbit models following topical administration. BI-1124 is primarily utilized in research focused on age-related dry eye disease, making it a valuable tool for exploring therapeutic interventions in ocular health.

Z-FG-NHO-Bz is a selective inhibitor of cathepsins, a family of cysteine proteases involved in various biological processes. This compound exhibits significant inhibitory activity against cathepsin B and L, making it a valuable tool for studying their roles in pathological conditions such as cancer and neurodegenerative diseases. Z-FG-NHO-Bz is ideal for research applications focused on proteolytic enzyme regulation and therapeutic intervention.

Dutacatib is a selective inhibitor of cathepsin K with demonstrated antiviral activity against SARS-CoV-2 3CLpro. By inhibiting cathepsin K, it plays a role in ameliorating bone diseases associated with cancer. This compound is valuable for research focused on therapeutic interventions in viral infections and bone-related pathologies in cancer.

SQ 32602 is a potent inhibitor of cathepsin E, exhibiting an IC50 value of 88 nM. This compound selectively inhibits cathepsin E activity, making it valuable for research into lysosomal function and proteolytic processes. SQ 32602 is suitable for studies involving cancer biology, autoimmune diseases, and other conditions where cathepsin E modulation may play a critical role.

NC 2300 is a selective and orally active inhibitor of cysteine cathepsins, specifically targeting cathepsin B, K, and S with IC50 values of 284, 34.5, and 186 nM, respectively. This compound is particularly useful in the study of diseases related to bone mineral disorders, enabling researchers to explore the role of cathepsins in these conditions and potential therapeutic interventions.

TB-11 is a potent Cathepsin D inhibitor, demonstrating an IC50 of 0.126 nM for Cathepsin D, alongside inhibitory activity of 1.92 nM for Cathepsin E and 48.8 nM for BACE1. This compound is valuable for research focused on tumor biology and the role of cathepsins in cancer progression. Its selectivity and potency make it a useful tool for investigating the therapeutic potential of Cathepsin D inhibition in various oncological studies.

Cathepsin K-IN-9 is a potent and selective inhibitor of Cathepsin K, exhibiting an IC50 of 6.2 nM. It demonstrates remarkable selectivity with IC50 values exceeding 10,000 nM for Cathepsins B, L, and S, providing over 1600-fold selectivity. With its excellent safety profile and metabolic stability, Cathepsin K-IN-9 is suitable for research applications in osteoporosis and other bone resorption-related studies.

MPI8 is an inhibitor of the major protease of SARS-CoV-2 (MPro) and cathepsin L, exhibiting significant antiviral activity. It functions through dual and selective inhibition of these key proteases, impacting the viral life cycle and host cellular processes. MPI8 is suitable for use in clinical studies targeting COVID-19 and contributes to understanding therapeutic strategies against SARS-CoV-2.

BML-244 is a potent inhibitor of cathepsin K, a cysteine proteinase involved in various pathological processes. This compound demonstrates significant biological activity in the context of inflammatory conditions, making it valuable for research applications related to rheumatoid arthritis (RA) and periodontitis. The inhibition of cathepsin K by BML-244 facilitates the exploration of its role in bone resorption and tissue remodeling, contributing to a better understanding of these diseases.

Cathepsin S-IN-1 is a potent inhibitor of Cathepsin S, a cysteine protease involved in the regulation of immune responses and antigen processing. By selectively targeting Cathepsin S, this compound can modulate inflammatory pathways and contribute to studies on autoimmune diseases, cancer, and other pathological conditions linked to protease activity. Its application in research may provide insights into therapeutic strategies aimed at inhibiting Cathepsin S-mediated processes.

MDL 27399 is a selective inhibitor of human neutrophil cathepsin G, exhibiting a Ki value of 7 μM. This compound is instrumental in studying the role of cathepsin G in inflammatory diseases, allowing researchers to explore potential therapeutic avenues for conditions characterized by excessive neutrophil activity.

Tasiamide B is a potent inhibitor of Cathepsin D and HSP90, derived from the marine cyanobacteria Symploca sp. This linear peptide serves as a valuable scaffold for the development of inhibitors targeting aspartic proteases. Tasiamide B has demonstrated significant efficacy in skin cancer studies by effectively interacting with HSP90, highlighting its potential in cancer research and therapeutic applications.

Cathepsin L-IN-6 is a selective inhibitor of cathepsin L, exhibiting an IC50 value of 0.021 μM. It functions by directly binding to cathepsin L, effectively suppressing its enzymatic activity. Additionally, Cathepsin L-IN-6 inhibits pro-inflammatory cytokines IL-6 and IL-8, demonstrating significant anti-inflammatory properties. This compound is particularly relevant for research focused on acute lung injury and related inflammatory conditions.

LV-320 is a potent uncompetitive inhibitor of cathepsin ATG4B, exhibiting an IC50 of 24.5 μM and a Kd of 16 μM. This compound effectively inhibits the enzymatic activity of ATG4B, thereby obstructing autophagic flux in cellular environments. Due to its stability and low toxicity, LV-320 is suitable for in vivo applications, making it a valuable tool for research on autophagy-related pathways.

(Rac)-Z-FA-FMK is a potent inhibitor of cathepsin B, exhibiting a Ki value of 1.5 μM. This compound also inhibits multiple caspases, specifically caspases 2, 3, 6, 7, and 9, with IC50 values ranging from 6.147 to 110.7 μM. Additionally, (Rac)-Z-FA-FMK demonstrates antiviral activity by inhibiting the main protease involved in SARS-CoV-2 replication with an IC50 of 11.39 μM. It further attenuates the increase in IL-1β levels induced by LPS and represses NF-κB transactivation in macrophages, making it useful for research in inflammation and viral pathogenesis.

Dual Cathepsin L/JAK-IN-1 is a dual inhibitor targeting Cathepsin L (CTSL) and Janus kinases (JAK), exhibiting IC50 values of 0.68 μM for CTSL, 337.1 nM for JAK1, 5.251 nM for JAK2, 27.29 nM for JAK3, and 172.6 nM for TYK2. This compound effectively inhibits the activation of key signaling pathways, including MAPK, NF-κB, and JAK/STAT, thereby providing substantial anti-inflammatory effects. Dual Cathepsin L/JAK-IN-1 is useful for investigating mechanisms underlying acute lung injury (ALI) and other inflammatory conditions.

TS-24 is a selective inhibitor of cathepsin S, demonstrating an IC50 value of 4.3 μM. This compound has been shown to exhibit radiosensitizing effects in wild-type BRCA1 and triple-negative breast cancer (TNBC) xenograft models, primarily by inducing apoptotic pathways. TS-24 is suitable for research applications focused on cancer therapeutic development and understanding cathepsin-mediated biological processes.

NCO-700 is a potent dual inhibitor of cathepsin B and calcium-activated neutral protease (CANP), exhibiting IC50 values of 0.8 μM and 46 μM, respectively. This compound effectively reduces myocardial fibrin degradation by inhibiting protease activity and demonstrates significant anti-tumor effects on hormone-independent cancer cells, including prostate cancer, by inducing apoptosis. NCO-700 serves as a valuable tool for investigating mechanisms underlying myocardial ischemia and exploring novel treatments for refractory hormone-independent tumors.

Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific inhibitor of cathepsin L (CTSL), a lysosomal cysteine protease involved in protein degradation and various pathological processes. It is commonly used as a tool compound in studies of CTSL-related functions and diseases.

Verducatib is an orally active inhibitor of cathepsin C, also known as Dipeptidyl Peptidase I (DPP1). By inhibiting the activation of neutrophil serine proteases, Verducatib restores the balance of proteases and inhibitors, thereby reducing pulmonary inflammation and enhancing responses to infection. This compound has demonstrated efficacy in decreasing the frequency and severity of acute exacerbations in bronchiectasis, while also improving lung function and quality of life. Its safety profile is comparable to placebo, with a slight increase in mild-to-moderate cutaneous adverse events at higher doses, indicating potential for clinical application.

Gallinamide A is a potent inhibitor of cathepsin L, demonstrating an IC50 value of 17.6 pM. This compound plays a crucial role in research applications focused on investigating the functions of cathepsin L in various biological processes, including protein degradation and immune response regulation. Its inhibitory activity makes Gallinamide A a valuable tool for studying the implications of cathepsin L in pathophysiological conditions.

Cathepsin-IN-5 is a selective inhibitor of cathepsins L and S, exhibiting IC50 values of 6.2 μM and 81 nM, respectively. This compound effectively inhibits cancer cell proliferation and induces apoptosis, while also reducing the growth of hepatocellular tumors in mouse models. Additionally, Cathepsin-IN-5 modulates the expression of genes associated with cell death and proliferation, making it a valuable reagent for research into hepatocellular carcinoma.